LAMY engages in developing a business tapping the eLearning market and the gaming market by teaching financial knowledge and resource management to children. The company is headquartered in St. Petersburg, Florida. The company went IPO on 2024-04-30. The firm is engaged in developing and manufacturing mammalian and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The platform enables the custom production of exosomes with genetic functionality, capable of selectively targeting specific cells to address diseases with unmet medical needs. The engineered exosomes have demonstrated the potential to target cancer stem cells, the primary drivers of recurrence and metastasis in various cancers, including glioblastoma and pancreatic cancer. Its proprietary manufacturing process utilizes plant-based materials to create exosomes used in various commercial applications, including dermatology and dentistry.
最新の財務諸表(Form-10K)によると、Thayer Ventures Acquisition II Corpの総資産は$0で、純損失は$0です。
LMMYの主要な財務比率は何ですか?
Thayer Ventures Acquisition II Corpの流動比率は0、純利益率は0、1株当たり売上高は$0です。
LAMYの収益はセグメントまたは地域別にどのように分けられていますか?
Thayer Ventures Acquisition II Corp の最大収益セグメントは American Eagle Net で、最新の利益発表における収益は 3,367,033,000 です。地域別に見ると、United States Net が Thayer Ventures Acquisition II Corp の主要市場であり、収益は 4,492,630,000 です。
LAMYは収益を上げていますか?
いいえ、最新の財務諸表によると、Thayer Ventures Acquisition II Corpの純損失は$0です。
LAMYに負債はありますか?
いいえ、Thayer Ventures Acquisition II Corpの負債は0です。
LAMYの発行済株式数は何株ですか?
Thayer Ventures Acquisition II Corpの総発行済株式数は5.83株です。